Harold Keer

Corporate Officer/Principal at Stanford University

Health Technology

Consumer Services

Profile

Harold Keer is a Clinical Faculty Member at Stanford University.
He previously worked as a Principal at Titan Pharmaceuticals, Inc., Vice President-Clinical Development at Exelixis, Inc., and Vice President-Clinical Development at Five Prime Therapeutics, Inc. Keer earned a doctorate degree from Northwestern University.

Harold Keer active positions

Companies	Position	Start
Stanford University	Corporate Officer/Principal	-

All active positions of Harold Keer

Former positions of Harold Keer

Companies	Position	End
EXELIXIS, INC.	Chief Tech/Sci/R&D Officer	-
TITAN PHARMACEUTICALS, INC.	Corporate Officer/Principal	-
FIVE PRIME THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	-

See the detail of Harold Keer's experience

Training of Harold Keer

Northwestern University

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Harold Keer's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
EXELIXIS, INC.	Health Technology
TITAN PHARMACEUTICALS, INC.	Health Technology

Private companies	1
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.	Health Technology